Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
Authors
Keywords
-
Journal
OncoImmunology
Volume 12, Issue 1, Pages -
Publisher
Informa UK Limited
Online
2023-10-17
DOI
10.1080/2162402x.2023.2255041
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer
- (2023) Florian Lordick et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
- (2023) Rui-hua Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
- (2023) Kohei Shitara et al. LANCET
- Intravenous Delivery of RNA Encoding Anti-PD-1 Human Monoclonal Antibody for Treating Intestinal Cancer
- (2022) Lipei Wu et al. Journal of Cancer
- Claudins and Gastric Cancer: An Overview
- (2022) Itaru Hashimoto et al. Cancers
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
- (2021) Florian Lordick et al. Gastric Cancer
- MRNA Delivery For Therapeutic Anti-Her2 Antibody Expression In Vivo
- (2019) Yulia Rybakova et al. MOLECULAR THERAPY
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
- (2019) O Türeci et al. ANNALS OF ONCOLOGY
- Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases
- (2019) Irene Coati et al. BRITISH JOURNAL OF CANCER
- A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection
- (2019) Nurgun Kose et al. Science Immunology
- A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer
- (2018) Ugur Sahin et al. EUROPEAN JOURNAL OF CANCER
- Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening
- (2018) Alexandra G. Orlandini von Niessen et al. MOLECULAR THERAPY
- Characterization of zolbetuximab in pancreatic cancer models
- (2018) Ӧzlem Türeci et al. OncoImmunology
- Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
- (2017) Christiane R Stadler et al. NATURE MEDICINE
- Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
- (2017) Norbert Pardi et al. Nature Communications
- Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer
- (2014) Patrick Micke et al. INTERNATIONAL JOURNAL OF CANCER
- Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms
- (2013) Stefan Wöll et al. INTERNATIONAL JOURNAL OF CANCER
- Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals
- (2011) Özlem Türeci et al. GENE
- Claudin-18 Is an Early-Stage Marker of Pancreatic Carcinogenesis
- (2011) Mariko Tanaka et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma
- (2011) Aya Shinozaki et al. VIRCHOWS ARCHIV
- New Markers of Pancreatic Cancer Identified Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8
- (2009) Zarir E. Karanjawala et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started